{
    "pmcid": "10060843",
    "qa_pairs": {
        "How can nanobodies be engineered to enhance their ability to target and neutralize viruses?": [
            "They can be engineered into bifunctional or bispecific antibodies.",
            "They can be engineered into monofunctional antibodies.",
            "They can be engineered into trifunctional antibodies.",
            "They can be engineered into non-specific antibodies."
        ],
        "What advantage do nanobodies have in terms of administration for targeting initial viral replication sites?": [
            "Their solubility allows for direct administration via inhalation.",
            "Their large size allows for oral administration.",
            "Their instability allows for intravenous administration.",
            "Their insolubility allows for topical administration."
        ],
        "What are nanobodies and how do they differ structurally from conventional antibodies?": [
            "Nanobodies are antibodies derived from camelids and cartilaginous fish, characterized by a single variable heavy chain domain (VHH) without a light chain.",
            "Nanobodies are antibodies derived from humans, characterized by a double variable heavy chain domain with a light chain.",
            "Nanobodies are antibodies derived from rodents, characterized by a single variable light chain domain without a heavy chain.",
            "Nanobodies are antibodies derived from birds, characterized by a double variable light chain domain with a heavy chain."
        ],
        "What is a challenge faced by nanobodies in the context of SARS-CoV-2 therapy?": [
            "Ensuring long-term efficacy and overcoming viral mutations.",
            "Ensuring short-term efficacy and overcoming bacterial mutations.",
            "Ensuring medium-term efficacy and overcoming fungal mutations.",
            "Ensuring immediate efficacy and overcoming parasitic mutations."
        ],
        "What is one method used to evaluate the efficacy of nanobody treatments in animal models?": [
            "Using transgenic hACE2 mice and hamsters to simulate SARS-CoV-2 infection.",
            "Using wild-type mice to simulate SARS-CoV-2 infection.",
            "Using non-transgenic rats to simulate SARS-CoV-2 infection.",
            "Using genetically modified rabbits to simulate SARS-CoV-2 infection."
        ]
    }
}